Increased Plasma Brain-Derived Neurotropic Factor, Not Nerve Growth Factor-Beta, in Schizophrenia Patients with Better Response to Risperidone Treatment
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Bun-Hee | - |
dc.contributor.author | Kim, Yong-Ku | - |
dc.date.accessioned | 2021-09-09T01:07:18Z | - |
dc.date.available | 2021-09-09T01:07:18Z | - |
dc.date.created | 2021-06-10 | - |
dc.date.issued | 2009 | - |
dc.identifier.issn | 0302-282X | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/122130 | - |
dc.description.abstract | Background: Some neurotropins, including brain-derived neurotropic factor (BDNF) or nerve growth factor-beta (beta-NGF), play important roles in neurodevelopment and neuroprotection. We examined the plasma levels of these 2 factors in schizophrenia patients at the time of admission and after 6 weeks of treatment with risperidone. Methods: Plasma BDNF and beta-NGF levels were measured in 36 schizophrenia patients and 36 healthy controls. All the patients underwent 6 weeks of treatment with risperidone. The severity of schizophrenia and response to treatment were assessed with the positive and negative syndrome scale (PANSS). We compared plasma BDNF and beta-NGF levels among much-improved (n = 13, 36.1%, >= 50% PANSS score reduction), minimal-improved (n = 15, 41.7%, >= 25% and < 50% PANSS score reduction) and nonresponse patients (n = 8, 22.2%, < 25% PANSS score reduction). Results: At baseline, plasma BDNF had no significant difference between schizophrenia patients and controls, but beta-NGF levels were significantly lower in schizophrenia patients than controls (p = 0.037). Plasma BDNF and beta-NGF in all schizophrenia patients had no significant changes between pre- and posttreatment. Baseline BDNF levels were significantly lower in nonresponse patients than others (p = 0.038). After treatment, much-improved patients had significantly higher plasma BDNF than nonresponse patients (p = 0.023). However, beta-NGF levels had no significant differences between them. Conclusions: Our data suggest that higher plasma BDNF levels might be associated with better response to risperidone treatment, while plasma beta-NGF levels might have no effect on the clinical response in schizophrenia patients. Copyright (C) 2009 S. Karger AG, Basel | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | KARGER | - |
dc.subject | CHOLINE-ACETYLTRANSFERASE EXPRESSION | - |
dc.subject | LONG-TERM TREATMENT | - |
dc.subject | BEHAVIORAL SENSITIZATION | - |
dc.subject | ATYPICAL ANTIPSYCHOTICS | - |
dc.subject | HIPPOCAMPAL-FORMATION | - |
dc.subject | RECEPTOR EXPRESSION | - |
dc.subject | DOPAMINE-RECEPTOR | - |
dc.subject | DECREASED LEVELS | - |
dc.subject | BLOOD-BRAIN | - |
dc.subject | BDNF LEVELS | - |
dc.title | Increased Plasma Brain-Derived Neurotropic Factor, Not Nerve Growth Factor-Beta, in Schizophrenia Patients with Better Response to Risperidone Treatment | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Yong-Ku | - |
dc.identifier.doi | 10.1159/000205518 | - |
dc.identifier.scopusid | 2-s2.0-61449144558 | - |
dc.identifier.wosid | 000264025900009 | - |
dc.identifier.bibliographicCitation | NEUROPSYCHOBIOLOGY, v.59, no.1, pp.51 - 58 | - |
dc.relation.isPartOf | NEUROPSYCHOBIOLOGY | - |
dc.citation.title | NEUROPSYCHOBIOLOGY | - |
dc.citation.volume | 59 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 51 | - |
dc.citation.endPage | 58 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Neurosciences & Neurology | - |
dc.relation.journalResearchArea | Psychiatry | - |
dc.relation.journalResearchArea | Psychology | - |
dc.relation.journalWebOfScienceCategory | Neurosciences | - |
dc.relation.journalWebOfScienceCategory | Psychiatry | - |
dc.relation.journalWebOfScienceCategory | Psychology | - |
dc.subject.keywordPlus | CHOLINE-ACETYLTRANSFERASE EXPRESSION | - |
dc.subject.keywordPlus | LONG-TERM TREATMENT | - |
dc.subject.keywordPlus | BEHAVIORAL SENSITIZATION | - |
dc.subject.keywordPlus | ATYPICAL ANTIPSYCHOTICS | - |
dc.subject.keywordPlus | HIPPOCAMPAL-FORMATION | - |
dc.subject.keywordPlus | RECEPTOR EXPRESSION | - |
dc.subject.keywordPlus | DOPAMINE-RECEPTOR | - |
dc.subject.keywordPlus | DECREASED LEVELS | - |
dc.subject.keywordPlus | BLOOD-BRAIN | - |
dc.subject.keywordPlus | BDNF LEVELS | - |
dc.subject.keywordAuthor | Brain-derived neurotropic factor | - |
dc.subject.keywordAuthor | Nerve growth factor-beta | - |
dc.subject.keywordAuthor | Risperidone | - |
dc.subject.keywordAuthor | Schizophrenia | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.